Qualia Oto has received a $1.84 million Phase II Small Business Innovation Research (SBIR) award from the National Institute on Deafness and Other Communication Disorders (NIDCD). The two-year grant will support continued research and development as the company advances toward commercialization of its shape-adaptive polymer technology for cochlear implant electrode arrays and the development of an FDA Device Master...
No actionable change — this is early-stage R&D funding news with no clinical data or product available yet.
NIH investment in next-generation cochlear implant electrode design signals continued federal commitment to improving outcomes for severe-to-profound hearing loss patients, potentially influencing future implant performance and surgical technique.
- 01Qualia Oto awarded $1.84M NIH NIDCD Phase II SBIR grant for cochlear implant electrode R&D.
- 02Grant funds two years of development on novel electrode technology.
- 03Phase II SBIR status indicates the technology has already passed initial feasibility review.
- 04No clinical trial data or human outcomes reported at this stage.
- 05Advancement could affect electrode design options available to surgeons and audiologists in future.
Qualia Oto has been awarded a $1.84M NIH NIDCD Phase II SBIR grant.
press releasesupportedThe grant will fund two years of R&D advancing cochlear implant electrode technology.
press releasesupported